Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-Label Study to Assess The Pharmacokinetics And Safety of Bimekizumab in Pubertal Children And Adolescents With Moderate to Severe Hidradenitis Suppurativa
Conditions
Interventions
Bimekizumab
Locations
18
United States
Hs0006 50175
Phoenix, Arizona, United States
Hs0006 50708
Roseville, California, United States
Hs0006 50684
Sacramento, California, United States
Hs0006 50707
Washington D.C., District of Columbia, United States
Hs0006 50199
Miami, Florida, United States
Hs0006 50178
Clarkston, Michigan, United States
Start Date
April 7, 2025
Primary Completion Date
December 21, 2026
Completion Date
March 6, 2029
Last Updated
March 27, 2026
NCT06958211
NCT05889182
NCT06993233
NCT06888193
NCT07316192
NCT06768671
Lead Sponsor
UCB Biopharma SRL
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions